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Currentlyinfectionwiththehumanimmunodeﬁciencyvirus-1(HIV-1)isinmostinstancesachronicdiseasethatcanbecontrolled
by eﬀective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including
signiﬁcant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated
receptor gamma (PPARγ) transcription factor is vital for the development and maintenance of mature and developing adipocytes.
Alterations in PPARγ expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both
reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question
remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type;
the mesenchymal stem cell. The possibility that dysregulation of PPARγ (and the subsequent eﬀe c to nb o t ho s t e o b l a s t o g e n e s i s
and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has
also been investigated. This review deals with the hypothesis that dysregulation of PPARγ may underpin the bone abnormalities
associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPARγ
involvement in HIV-1-associated bone disease.
Copyright © 2009 Eoin J. Cotter et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Aside from the serious eﬀects on the cells of the immune
system, HIV-1 infection and its treatment have been asso-
ciated with disorders in other tissues, most notably bone
[1, 2] and adipose [3–6] tissues, where reduced bone mineral
density (BMD) and abnormalities of the lipid metabolism
(lipodystrophy, dyslipidemia, and insulin resistance) have
been described. In both disorders (particularly those of the
adipose tissue), antiretroviral treatment is believed to play
a major role, but the contribution of underlying HIV-1
infection has yet to be elucidated, and therefore cannot be
ignored as a potential causative factor.
PPARγ is a nuclear membrane bound transcription
factor which regulates a number of genes involved in adi-
pogenesis from common precursor cells type (mesenchymal
stemcells),maturation of preadipocytes, lipid accumulation,
and maintenance of adipogenic phenotype [7, 8]. As such,
it is not surprising that a number of recent studies have
indicated that certain drugs known to be associated with
lipodystrophy dysregulate PPARγ [9, 10]. The involvement
of PPARγ in HIV-1-associated bone disease is an area that
has been little studied to date; however numerous studies
suggest that PPARγ plays a role in conditions such as
osteoporosis in the absence of HIV-1 or ART, and increased
adipocyte content of osteoporotic bone has been reported
[10–12]. In addition, osteoblasts—the cells responsible for
depositing bone—are derived from mesenchymal stem cells,
andevidencesuggeststhatthebalanceofPPARγ andthepro-
osteogenic runt-related transcription factor-2 (RUNX-2) is a
key in the determination of mesenchymal stem cell fate [13–
15] (see Figure 1). This review will introduce the current
knowledge of the role of PPARγ in bone biology in normal
and disease states, and discuss its potential as a mechanism
for HIV-1-associated bone disease.
2.HIV-1-AssociatedBoneDisease
Osteoporosis is deﬁned as a reduction in the bone mass
and disruption of the microarchitecture of the bone which
leads to a greatly increased risk of fractures, while osteopenia2 PPAR Research
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Figure 1: Factors governing normal osteogenesis and adipogenesis
from mesenchymal stem cells. Multipotent mesenchymal stem cells
can diﬀerentiate into a number of cell types, including adipocytes
and osteoblasts. (⊥ indicates inhibition; ↓ indicates stimulation).
The transcriptional coactivator Taz negatively regulates adipoge-
nesis and promotes osteogenesis through suppression of PPARγ
and activation of RUNX-2, while overexpression of PPARγ can
reduce bone formation. Also, a number of other factors such as
secreted proteins from Wnt family promote the diﬀerentiation and
maintenance of osteoblasts while reducing the diﬀerentiation of the
adipocytes. In addition, factors secreted by mature adipocytes, such
as leptin and estrogen, can increase bone mass in vivo.
is a lesser reduction in bone density and strength which
may remain asymptomatic, but can precede actual osteo-
porosis. The world health organization (WHO) deﬁnitions
specify t-scores between −1a n d−2.5 as being indicative of
osteopenia, while t-scores of less than −2.5 are indicative
of osteoporosis [16]. Fractures resulting from osteoporosis
aﬀect one in two women and one in ﬁve men over the age of
50, and are a signiﬁcant ﬁnancial burden to health services,
with an estimated combined annual cost of 30 billion Euro
in the EU [17].
As will be discussed further, bone remodeling is depen-
dent on the opposing functions of two cell types, osteoblasts,
which make new bone (bone formation), and osteoclasts,
which destroy old bone (bone resorption). Therefore, the
balance between the number and activity of osteoclasts and
osteoblastsiscrucialinnormalbonehomeostasis;thepertur-
bation of which can directly lead to increased bone fragility
and fracture risk. Two important molecules: macrophage
colony-stimulating factor (M-CSF) and receptor for activa-
tion of nuclear factor-kappa B ligand (RANKL) produced
from osteoblast/stromal cells regulate the diﬀerentiation,
function, and survival of osteoclasts, while the transcription
factors, RUNX-2 and Osterix, have been reported to regulate
osteoblast diﬀerentiation [18].
2.1. HIV-1 Infection and Bone Disease. Bone metabolism
in HIV-infected individuals has been studied since the late
1980s, although the number of early studies is somewhat
limited. Before the widespread use of highly active ART,
studies indicated that bone mineral metabolism was only
minimally aﬀected in HIV-infected patients. Serrano et al.
assessed histomorphometry in HIV-positive patients and
found that parameters of histomorphometry such as serum
osteocalcin were found to be lower in patients who, accord-
ing to the Centers for Disease Control (CDC) classiﬁcation,
had greater disease severity [19]. Paton et al. reported that
45 HIV-infected patients had marginally lower BMD at
the lumbar spine. None of the patients had reduced BMD
to levels associated with a diagnosis of osteoporosis [20].
More recently however, it became clear that reduced BMD
is also frequent in the absence of therapy [21–24]. In a
study by McGowan et al., the prevalence of osteopenia
among antiretroviral-naive HIV-positive individuals to be
approximately 28%, which is approximately 50% greater
than the expected incidence in the general, uninfected
population [25]. Studies which have included patients with
more advanced HIV disease who have received treatment for
longer periods have reported prevalence of 40% to 50% [26,
27], placing reduced BMD among the most common HIV-
1-associated metabolic toxicities. Amiel et al. also assessed
BMD in 48 HIV-infected treatment-naive patients, 49 HIV-
infected patients on protein inhibitors, 51 HIV-infected
patients on no-protein inhibitors, and 81 HIV-uninfected
control subjects. The results showed a signiﬁcant decrease
of BMD (9%) in all HIV-infected patients compared to the
control subjects, occurring concurrently with a lower bone
alkaline phosphatase and higher urinary cross-laps/Cr. [28].
The clinical impact of this reduced BMD is beginning to
be examined; recent studies in a large American health care
system, involving 8526 HIV infected patients and over 2
million control subjects, demonstrated that the prevalence
of any fracture type was signiﬁcantly higher in the HIV-
infected population (2.87 versus 1.77 fractures/100 persons,
P = .002). This study did not specify the treatment status
of their subjects, but the data suggests that HIV-1-related
fractures are a signiﬁcant and growing clinical issue [29].
2.2. Antiviral Treatment and Bone Diseases. Antiretroviral
treatment (ART) is a complex therapeutic regimen, in which
patients typically take 2-3 agents selected from an array of
30approvedantiretroviralagents.ART,ingeneral,comprises
of two major therapeutic strategies: a protease inhibitor-
(PI-) based regimen and a nucleoside reverse transcriptase
inhibitor- (NRTI-) based regimen. The PI-based regimen
uses one or two PIs combined with two NRTIs, whereas
the NRTI-based regimen uses two NRTIs combined with
onenon-nucleosidereversetranscriptaseinhibitor(NNRTI).
With more eﬀective therapies as a result of HAART, the
prevalence of HAART-associated bone diseases has increased
[30].
A higher incidence of reduced BMD has been clin-
ically associated with both PI and NRTI uses. Tebas et
al. determined that in HIV-1 patients receiving PIs about
50% of the patients had osteopenia and other 21% had
osteoporosis [31]. This incidence is signiﬁcantly increasedPPAR Research 3
compared to patients without therapy or normal controls.
Studies by Moore et al. conﬁrmed that 71% of HIV-
infected patients on PI therapy have reduced BMD [32].
Similarly, Carr et al. reported that 3% of 44 HIV-infected
patients receiving NRTIs developed osteoporosis and 22%
developed osteopenia [33], while in a study examining
HIV-1-infected men Mallon determined a reduction in
BMD beginning at 48 weeks postinitiation of treatment
[6]. Tsekes et al. determined BMD and whole body fat
by dual energy X-ray absorbance (DEXA) of HIV-infected
patients receiving zidovudine and other NRTIs and found
signiﬁcant decreases in both body fat and BMD [34]. In
addition, the recent analysis by Brown and Qaqish [35]
also reported 2.5-fold increased odds of reduced BMD in
ART-treated patients compared with ART-naive patients
(95% CI 1.8, 3.7). However, most studies are in agreement
that traditional risk factors for osteoporosis, such as ethnic
variations, female sex, increasing age, low body mass index,
and time since menopause, are all independent predictors of
osteopenia/osteoporosis [36–40].
In addition, it has been noted that HIV-infected patients
have an increased risk for osteonecrosis of the hip [41].
Keruly et al. reported 15 cases of avascular hip necrosis
in HIV-infected patients and suggested that the incidence
of osteonecrosis in HIV-infected patients was higher than
the general HIV-negative population [42]. It is not known
whether this phenomenon is attributable to HIV-1 infection
itself, HAART, or other HIV-associated complications.
The mechanisms by which either HIV-1 or its treatment
induces reduced BMD are as yet unclear, and several
researchers have suggested that reduced vitamin D lev-
els observed in HIV-1-infected patients, and particularly
the reduced levels of the biologically active metabolite
1,25(OH)2D (which is the natural ligand for the vitamin
D receptor (VDR)), may contribute to reduced BMD [43].
Studies have demonstrated that the level of 1,25(OH)2Di n
HIV-1-infected patients is between 5 and 50% lower than
thatininfectedpatients[24,44,45].Inaddition,studieshave
indicated that patients receiving treatment are more likely to
have greater reductions in 1,25(OH)2D, with a recent Dutch
studysuggestingthatNNRTItreatmentmayincreasetherisk
of vitamin D deﬁciency [46, 47]. In addition, the latter study
demonstrated that patients receiving treatment also have
increased parathyroid hormone (PTH) levels, increasing the
potential risk of reduced bone mass.
In short, HIV-1-associated bone disorders are a signif-
icant and increasingly well-deﬁned clinical issue. However,
the molecular basis underpinning these clinical observations
remains to be fully explained.
3. PPARγ:MediatorofDevelopmentand
DiseaseinBone Biology
As discussed previously, maintenance of bone homeosta-
sis is mediated through a balance of osteoblast-mediated
bone deposition and osteoclast-mediated bone resorption.
The continued production of these cells from stromal
(mesenchymal) and hematopoietic (monocyte) precursors,
respectively, is an essential component in the maintenance
of BMD. Stromal progenitor or mesencymal stem cells are
multipotent cells, capable of producing cells of a number
of diﬀerent lineages, including osteoblasts and adipocytes
[47–49].
Since the early 1990s, researchers have hypothesized that
a “see-saw” relationship exists in the bone marrow cavity,
whereproductionofadipocytesfromstromalprecursorsisat
the expense of osteoblast production and vice versa [50, 51].
Thistheoryisbornoutbyaclinicallyobservedphenomenon,
such as the increased adipocyte content of osteoporotic and
aging bone [51–53] as well as studies where agents inducing
adipocyte production reduced osteoblast number [49, 50].
Likewise, treatment of bone marrow stromal cells with bone
morphogenicproteins(BMPs)resultedinreducedformation
of adipocytes [53]. Adipocytes can also produce secreted fac-
tors such leptin and estrogen, which can positively regulate
bone mass [13, 54, 55], further underlining the interrelated
nature of bone and fat development (see Figure 1).
PPARs are ligand-activated nuclear hormone receptors
which stimulate expression of genes containing peroxisome
proliferator response elements (PPREs) [53, 54]. There are
three principal members of this family, PPARα,P P A R δ,
and PPARγ, activation of which stimulates genes involved
in fatty acid oxidation, uncoupling of respiration toward
heat production (thermoregulation) and terminal adipocyte
diﬀerentiation (including intracellular lipid accumulation),
respectively, (see Table 1)[ 49, 50, 55–59].
The activity of PPARγ a n dR U N X - 2i sak e yt oo u r
understanding of the relationship between fat and bone.
Activity of the RUNX-2 transcription factor is not only
essential for maintenance of osteoblast phenotype, but it
is also involved in driving the diﬀerentiation of osteoblasts
from mesenchymal stem cells [11–14], while activity of
PPARγ in mesenchymal stem cells induces diﬀerentiation
into adipocytes. The eventual phenotype of the diﬀeren-
tiating cell is generally considered to be controlled by an
antagonistic balance between RUNX-2 and PPARγ [13, 14].
Studies have demonstrated, for example, that activation of
PPARγ using pharmacological agents can lead to decreased
bone mass in vivo, while mice lacking the PPARγ gene
display increased bone mass and an inability to develop
adipocytes [59–61]. Indeed, even in the eventual mature cell,
the function can be altered by dysregulating this balance,
with in vivo studies using a mouse model demonstrating
reduced bone formation rate and suppression of RUNX-
2 in osteoblasts in which PPARγ had been activated [61],
while Kim et al. have demonstrated that activation of PPARγ
induces death through a MAPK-dependant mechanism in
osteoblastic cells [62].
PPARγ deﬁcient mice (having a mutation in the PPARγ2
locus) have been generated and display a “lipodystrophic”
phenotype, which occurs concurrently with increased bone
mass, to the point where the bone marrow is almost com-
pletelyoccludedandhematopoiesismovestoextramedullary
sites, suchas thespleen[61,63].Recently,our understanding
of the roles of PPARγ in numerous physiologic processes,
including the bone/fat paradigm, has been furthered by
the development of the thiazolidinedione (TDZ) family of4 PPAR Research
Table 1:PPARγ-regulatedgenesinvolvedinadiogenesis,glucoseuptake,andthermoregulation(↑positiveregulation; ↓negativeregulation).
PPARγ-regulated genes
Gene Tissue/cell type Function
CCAT enhancer binding protein α
(CEBPα)[ 7]↑ Adipose/preadipose tissue Transcription factor. CDK2/4
inhibition-cell cycle arrest
Adipose diﬀerentiation related
protein (ADRP) [50]↑ Adipose/preadipose tissue
Associated with globule membrane,
early marker of adipocyte
diﬀerentiation
Lipoprotein lipase [49]↑ Vascular endothelium, heart,
muscle, adipose Lipid hydrolysis from lipoproteins
Adiponectin [49]↑ Adipose tissue (secreted) Fatty acid catabolism
Adipocyte protein 2 (aP2/FABP4)
[49]↑ Adipocytes/macrophages Intercellular lipid transport
Tumour suppressor candidate 5
(TUSC 5) [56]↑ Preadipose/adipose tissue Associated with entry into the later
stages of adipogenesis
Glucose transporters 4 (GLUT) 4
[57]↑ Wide tissue distribution Insulin stimulated glucose uptake
Uncoupling proteins 1-3 (UCP 1-3)
[58]↑ Adipose tissue, skeletal muscle, liver Thermogenesis/thermoregulation
PPARγ ligands, such as netoglitazone, pioglitazone, rosigli-
tazone, and GW0072 [64–67] .S t u d i e sh a v ed e m o n s t r a t e d
that treatment of murine osteoblasts with netoglitazone
and GW0072 can block osteoblast diﬀerentiation, without
inducing adipogenesis [62, 64], while in vivo studies have
demonstrated that rosiglitazone, a ligand with higher aﬃnity
for PPARγ, decreased bone mineral density, bone forma-
tion rate, and trabecular bone volume, while increasing
adipogenesis [65, 67]. Further studies on ovariectomized
rats revealed that these eﬀects are mediated in part by
the suppression of the RUNX-2 transcription factor [67],
giving further strength to the argument that an antagonistic
relationship between PPARγ and RUNX-2 governs bone and
fat formation. Indeed, Hong et al. have demonstrated that
shared coactivator protein, TAZ, accounts in some part for
this relationship, in that it coactivates RUNX-2 and bone
formation, while suppressing PPARγ [68].
3.1. PPARγ in HIV-1-Associated Lipodystrophy. ART is asso-
ciated with changes in fat metabolism, broadly termed
lipodystrophy (changes in fat distribution) or lipoatrophy
(atrophy of adipose tissue). Severe forms of lipodystrophy
are a major cosmetic concern, and can lead to suboptimal
adherencetotherapy.Inaddition,lipodystrophyisassociated
withmarkersofcardiovascularrisk,suchasinsulinresistance
and dyslipidemia [5].
In vitro, expression of PPARγ is decreased by expo-
sure to anti-HIV-1 PI and NRTI drugs. In diﬀerentiating
adipocytes, exposure to nelﬁnavir, saquinavir, and ritonavir
at 10μM concentrations resulted in decreased adipogenesis
and expression of the PPARγ-mediated mRNA encoding
aP2 and lipoprotein lipase (LPL) [10]. Similar eﬀects on
PPARγ expression were observed in 3T3-F442A adipocyte
cells exposed to 10–50μM indinavir [69], while studies by
the same group have also demonstrated that the nuclear
association of the PPARγ regulator SREBP-1 is reduced
by treatment with indinavir [70]. In mature adipocytes,
inhibition of PPARγ function by expression of a dominant
negative PPARγ isoform results in decreased accumulation
ofintracellulartriglyceride,decreasedcellsize,anddecreased
expression of genes involved in both fatty acid and glucose
metabolism, including the glucose transporter GLUT-4 [71].
In lipoatrophic mice, ablation of PPARγ activity in liver
resulted in hepatic steatosis, hypertriglyceridemia, and mus-
cle insulin resistance [72]. Many of these features are shared
by PI-treated patients with HIV-1-associated lipodystrophy.
In vivo, patients with lipodystrophy had lower adi-
pose tissue expression of both PPARδ and PPARγ than
those without lipodystrophy. This was accompanied by
decreases in a number of PPARγ-responsive downstream
genes including LPL and GLUT-4 [73, 74]. In studies by
Mallon, NRTI treatment of non-HIV-1-infected subjects
(either stavudine/lamivudine or zidovudine/lamivudine for
six weeks) resulted in reduced PPARγ expression in adipose
tissue (alongside alterations in transcription of mitochon-
drial DNA, and upregulation of genes associated with
mitochondrial transcriptional regulation), although in this
study the eﬀects on overall fat mass were not determined [9].
In patients with type 2 diabetes, exposure to TZD, which
act as PPARγ ligands, resulted in increased expression of
PPARγ-target genes such as LPL and fatty acid synthase
(FAS) in subcutaneous adipose tissue biopsies, without
increasing expression of PPARγ itself [71]. However, studies
utilizing TZD to treat lipodystrophy have produced variable,
and at best, modest results [75–78]. More recently, van
Wijk et al. demonstrated that rosiglitazone treatment, com-
pared to treatment with metformin, increased subcutaneous
abdominal and visceral abdominal fat in lipodystrophy,
however this was a small study (n = 39), was not blinded or
placebo controlled, and did not measure clinical outcomes
[79].
The weight clinical and scientiﬁc evidence suggests that
HIV-1/ART-associated lipid abnormalities occur largely asPPAR Research 5
a result of treatment rather than infection. However, a
recent study raised the possibility that there may also be a
viral component; Shrivastav et al. [80] demonstrated that
treatment with the HIV-1 accessory viral protein R (Vpr)
could suppress PPARγ-induced transactivation in 3T3-L1
murine adipocyte cells, with a consequent inhibition of
adipocyte diﬀerentiation. Vpr is a 96-amino-acid accessory
protein, which is packaged in the viral capsid, and is found
in the nucleus early after cell infection [81, 82]. Among
the functions of Vpr is its ability to act as a transcriptional
activator of viral and cellular promoters [83–86]. Vpr
enhancestheactivityofsteroidhormonereceptors,including
the gluticorticoid receptor (GR), which Vpr can bind via
its LXXLL motif [85]. Studies involving cotransfection with
constructs expressing wild type and mutant (LXXLL null)
VprconstructswithreporterconstructscontainingthePPRE
demonstrated that this phenomenon was dependent on the
LXXLL motif. Further experiments demonstrated that the
GR did not play a role, and that Vpr and PPARγ interacted
directly in living cells. The authors of this study hypothesize
that in vivo circulating Vpr, or Vpr produced as a result of
direct infection of adipocytes, could suppress diﬀerentiation
of preadipocytes in a PPARγ dependent manner with
obvious consequences for the development of lipodystrophy
and insulin resistance [80].
3.2. PPARγ in HIV-1-Associated Bone Disease. In contrast to
the clearly deﬁned role for PPARγ in HIV-1/ART-associated
lipid abnormalities, few studies have focused on its potential
impact in HIV-1/ART-associated bone abnormalities.
To date, studies into mechanism of reduced bone density
have been understandably focused on two distinct strands,
namely, the eﬀects on osteoblast and osteoclast number
and function. In the case of OC research, several studies
have demonstrated that osteoclast function can be altered
in vitro by treatment with both ritonavir and HIV-1 gp120
[87, 88]. Jain et al. demonstrated that osteoclast activity,
measured using a rat neonatal calvaria assay, increased in
the presence of nelﬁnavir, indinavir, saquinavir, or ritonavir,
while lopinavir and amprenavir did not increase osteoclast
activity. In addition, Pan et al. reported a signiﬁcant increase
in markers of osteoclastogenesis (namely, the activity of
the tartaric acid phosphatase (TRAP) promoter and the
NF-κb transcription factor) in RAW264.7 (mouse leukemic
monocyte macrophage cell line cells) and primary mouse
osteoclast precursors treated with the NRTI zidovudine [89].
This same group has more recently reported that the NRTIs
ddi and lamiduvine also induced osteoclastogenesis in vitro
and osteopenia in an in vivo mouse model [90].
Similarly, osteoblast-based studies have produced some
interesting data. Clinically, Serrano et al. reported reduced
numbers of osteoclasts in HIV patients; a phenomenon
occurring along side-reduced serum osteocalcin levels and
bone formation rate [19]. Previous and ongoing in vitro
studies by our own group have demonstrated that osteoblast
activity (as measured by calcium deposition and alkaline
phosphatase activity) can be reduced by a number of
antiretroviral drugs (including both nelﬁnavir and indi-
navir). In addition, these studies identiﬁed tissue inhibitor
of metalloproteinase-3 (TIMP-3) as a mechanism for this
observed loss in osteoblast function [91]. Further studies
by our group demonstrated that treatment with the HIV-
1 proteins p55-gag and gp120 reduced osteoblast activity
in conjunction with reduction RUNX-2 transcription factor
activity [92]. Interestingly, gp120 both decreased RUNX-
2 activity and increased PPARγ. Furthermore, our studies
investigating the eﬀect of HIV-1 proteins on mesenchymal
stem cell diﬀerentiation have suggested that the proteins
p55 and REV alter both mesenchymal stem cell osteoblastic
diﬀerentiation and RUNX-2/PPARγ signalling in nondiﬀer-
entiating mesenchymal stem cells [93].
Althoughthesestudiesusedasomewhatsimplisticmodel
of HIV-1 exposure, given the evidence of the impact of
PPARγ on normal bone biology, and the observation that
it can be perturbed in HIV-1-associated lipodystrophy, it
is tempting to interpret these results as being suggestive of
PPARγ playing a role in HIV-1-mediated bone disease. How-
ever, there is an obvious stumbling block for this hypothesis,
namely, that if increased PPARγ activity in mesenchymal
stem cell and osteoblasts could result in reduced bone
mass, it would surely also increase fat mass. This picture
is further complicated, as previously discussed studies have
demonstratedthattreatmentofnon-HIV-1-infectedsubjects
with NNRTIs resulted in reduced PPARγ expression in
adipose tissue [9], while in vitro studies with 3T3-F442A
cells have demonstrated that both PPARγ expression and
its association with SREBP-1 are reduced by treatment
with indinavir [69, 70]. However, diﬀerent processes may
govern fat redistribution in diﬀerent tissues, with gain in
visceral fat and loss of subcutaneous fat. In addition, at least
one ex vivo study suggests that both markers of adipocyte
and osteoblastic diﬀerentiation are signiﬁcantly reduced in
human mesenchymal stem cells treated with a subset of pro-
tease inhibitors (particularly nelﬁnavir and saquinavir) [94],
while HIV-1 patients receiving the NRTI zidovudine were
shown to have reduced both BMD and whole body fat [33].
Could it be that contributing to both HIV-1/ART-associated
bone and lipid disorders is an underlying disregulation of
mesenchymal stem cell function combined with separate
eﬀects on adult or partially diﬀerentiated cells?
4. Conclusion
The importance of PPARγ in both bone and fat metabolism
has been clearly demonstrated, and while a role for PPARγ
in the lipid abnormalities associated with HIV-1 and its
treatment is emerging, its involvement in HIV-1-associated
bone disease remains unclear. Given the common origin of
bothadipocytesandosteoblastsfrommesenchymalstemcell,
and the demonstrated eﬀect of increased PPARγ expression
on bone in vitro and in vivo, we hypothesize a potential
role for PPARγ in the reduced bone mass associated with
HIV-1 infection and treatment. It may be possible that HIV-
1 infection and/or treatment, through dysregulating PPARγ
(and possibly also RUNX-2) activity in undiﬀerentiated
stromal cells, or in partially diﬀerentiated preosteoblast6 PPAR Research
and preadipocyte cells, can reduce the eventual number or
functional capacity of the adult cell types.
In order to further investigate this hypothesis, it may
be worthwhile to conduct ex vivo experiment on primary
mesenchymal stem cells collected from HIV-1 patients.
The expression and activity of PPARγ and diﬀerentiation
potential of these cells could be assessed and compared to
those of cells harvested from uninfected individuals, and
the data gathered used to generate a new model of HIV-
1/PPARγ/mesenchymal stem cell interactions.
It is clear that further studies are necessary to more fully
describe the role of PPARγ in the setting of HIV-1-associated
bonediseaseanditsinterplaywithvascularandfatdisorders.
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